<DOC>
	<DOC>NCT02072967</DOC>
	<brief_summary>Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the second line therapy of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma</brief_summary>
	<brief_title>Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Doctor's decision to prescribe Ribomustin and rituximab combined therapy for the treatment of relapsed or refractory indolent Bcell NonHodgkin's Lymphoma (iNHL) Informed Consent Form for personal data handling signed by the program participant, authorized by the Independent Ethics Committee Eastern Cooperative Oncology Group (ECOG) status &lt; 2. Confirmed relapse or disease progression of Bcell CD20+ NonHodgkin's Lymphoma (lymphocytic, lymphocytoplasmocytic, follicular, marginal zone) after minimum one line of iNHL treatment Patients with relapsed or refractory indolent Bcell NonHodgkin's Lymphoma with current or planned Ribomustin and rituximab combined therapy with following rituximab maintenance therapy Indolent NonHodgkin's Lymphoma transformation Lymphoma with central nervous system (CNS) involvement Presence of second malignant tumor. Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment. Contraindications for Ribomustin usage in accordance with product label Contradictions for rituximab usage in accordance with product label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Bendamustine</keyword>
</DOC>